AI Analysis AI Analysis of HROW
Powered by GPT-4o
Stock Analysis
Risk Assessment
Trading Strategy
PDF

Imprimis Pharmaceuticals stock price fell more than -5.70% Wednesday closing at $29.94
(Updated on Feb 12, 2025)

Sell candidate since Feb 11, 2025 Loss -5.70%

The Imprimis Pharmaceuticals stock price fell by -5.70% on the last day (Wednesday, 12th Feb 2025) from $31.75 to $29.94. During the last trading day the stock fluctuated 6.03% from a day low at $29.63 to a day high of $31.41. The price has fallen in 6 of the last 10 days and is down by -7.45% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -225 thousand shares and in total, 335 thousand shares were bought and sold for approximately $10.03 million.

The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $28.37 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -24.15% during the next 3 months and, with a 90% probability hold a price between $21.52 and $29.80 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Investment opportunities can be found at any hour. So, react immediately to market-moving news and capture more market opportunities when convenient for you. You can trade over 10,000 US Stocks and ETFs, US Equity Index options, US Treasuries – and more - around the clock . Interactive Brokers’ dual market centers ensure reliable and dependable overnight trading on your timetable. (Member SIPC)
IBKR Logo

HROW Signals & Forecast

A buy signal was issued from a pivot bottom point on Monday, February 03, 2025, and so far it has risen 0.369%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Imprimis Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $31.02 and $33.45. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Imprimis Pharmaceuticals stock

Imprimis Pharmaceuticals finds support from accumulated volume at $29.83 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.79 between high and low, or 6.03%. For the last week, the stock has had daily average volatility of 5.44%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (HROW) For The Upcoming Trading Day Of Thursday 13th

For the upcoming trading day on Thursday, 13th we expect Imprimis Pharmaceuticals to open at $30.33, and during the day (based on 14 day Average True Range), to move between $28.12 and $31.76, which gives a possible trading interval of +/-$1.82 (+/-6.08%) up or down from last closing price. If Imprimis Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 12.17% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $29.83 (0.37%) than the resistance at $30.72 (2.61%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Imprimis Pharmaceuticals stock A Buy?

Imprimis Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -3.988 Sell Candidate Unchanged

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

Predicted Fair Opening Price

Predicted fair opening price on February 13, 2025 - $30.33 ( 1.29%).

HROW Performance

Trading levels for HROW

Fibonacci Support & Resistance Levels

Level Price
R3 32.11 7.25%
R2 31.43 4.97%
R1 31.01 3.56%
Price 29.94
S1 29.64 -0.99%
S2 29.22 -2.40%
S3 28.54 -4.68%

Accumulated Volume Support & Resistance Levels

Level Price
R3 37.42 24.98%
R2 31.75 6.05%
R1 30.72 2.61%
Price 29.94
S1 29.83 -0.367%
S2 0 -
S3 0 -

FAQ

What is the symbol for Imprimis Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Imprimis Pharmaceuticals is HROW and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Imprimis Pharmaceuticals Stock?
Imprimis Pharmaceuticals holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Imprimis Pharmaceuticals Stock?
Imprimis Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Imprimis Pharmaceuticals Stock.

What's the current price of Imprimis Pharmaceuticals Stock?
As of the end of day on the Feb 12, 2025, the price of an Imprimis Pharmaceuticals (HROW) share was $29.94.

What is the 52-week high and low for Imprimis Pharmaceuticals Stock?
The 52-week high for Imprimis Pharmaceuticals Stock is $59.23 and the 52-week low is $9.30.

What is the market capitalization of Imprimis Pharmaceuticals Stock?
As of the Feb 12, 2025, the market capitalization of Imprimis Pharmaceuticals is 1.14B.

When is the next earnings date for Imprimis Pharmaceuticals?
The upcoming earnings date for Imprimis Pharmaceuticals is Mar 18, 2025.
Click to get the best stock tips daily for free!
ABOUT IMPRIMIS PHARMACEUTICALS
Imprimis Pharmaceuticals
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma...
GOLDEN STAR
Ticker Change Signal Date
LFUS
$234.72
3.32% Feb 10
ITW
$255.56
0.192% Feb 07
O
OBDC
$15.00
2.20% Feb 07
GGB
$2.95
2.37% Feb 06
BUD
$49.11
6.45% Feb 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE